CSIRO Molecular & Health Technologies

The bioeconomy will provide a platform to a sustainable future by providing security of food, water and energy supplies, reduced emissions, and the sustainable use of both biological and non-biological resources.

The bioeconomy is an emerging term for the sustainable production and conversion of biomass for a range of food, health, fibre and industrial products and energy.

CSIRO scientists have developed a new system to screen for compounds that can inhibit one of the processes that takes place during the progression of Alzheimer’s disease.

AusBiotech will hold its 2008 conference, Building a Bioeconomy - climate, food, health, investment, fuel at the Melbourne Convention Centre 26 – 29 October 2008.

An exciting conference that will bring together international world leaders in polymer sciences and industry leaders to share perspectives and work towards producing superior products for the marketplace into the future.

AusBiotech 2008 is a comprehensive conference program and bioindustry exhibition which aims to bring together representatives from the global biotechnology industry.

The goal of CSIRO’s Medical Imaging for Early Disease Detection research theme is to improve health and wellbeing by reducing the impact of diseases.

New sophisticated polymer platforms for the improved delivery of small-molecule and biological therapeutics.

CSIRO is developing membranes for desalination, purification of gases and many other commercial uses.

CSIRO can develop new, composite materials to improve the design and fabrication of products, and introduce new qualities such as lightness and corrosion resistance.

This video discusses the winning of a CSIRO Medal for Research Achievement 2006 by Dr Colin Ward and his team for the development of the insulin receptor. (2:30)

This video looks at how CSIRO solved the structure of a flu virus surface protein and led the development of the first anti-viral flu drug effective against all strains of flu. (3:00)

Dr Megan Fisher is acting Chief of CSIRO Molecular and Health Technologies, she has tertiary qualifications in science and business and an outstanding track record in strategic management, business development and technology commercialisation.

Dr John Tsanaktsidis has returned to CSIRO following a successful stint at managing a CSIRO spin-out company, Boron Molecular Pty Ltd.

A snapshot of CSIRO’s commercial opportunities and highlights of our portfolio companies. (35 pages)

This six-page brochure describes how the emerging bioeconomy is providing a platform to a sustainable future.

A fact sheet with information for submissions for the Materials of the future, science of today conference. The conference will explore Radical Polymerisation and CSIRO’s RAFT (Reversible Addition-Fragmentation chain Transfer) technology, which has generated intense international scientific and industrial interest. (1 page)

CSIRO’s IP is a platform technology for the rapid expansion of cells whilst maintaining phenotype. The technology will be useful for a wide range of cellular therapies and tissue engineering applications. (2 pages)